NRC Health Reports Q3 2026 Growth Driven by Increased Contract Value and Sales Pipeline
NRC Health (NRC) reported its third-quarter 2026 earnings, highlighting an 11% increase in Total Recurring Contract Value (TRCV), which reached $151.9 million. While upfront investments in implementation capacity for large health system contracts have kept adjusted EBITDA margins steady at 27%, management expects margin expansion in the second half of the year as these contracts begin to drive revenue. The company is positioned for significant growth through product cross-selling, noting that approximately 71% of its current customer base utilizes only a single product line. Additionally, NRC Health successfully navigated market disruption caused by the merger of competitors Qualtrics and Press Ganey, resulting in a 60% year-over-year increase in sales pipeline generation.
Tickers: $NRC
Topics: EBITDA margins Revenue expansion Sales pipeline growth Total Recurring Contract Value
Read the full article at Motley Fool
Part of the story Docebo Reports Q3 2026 Growth Driven by Enterprise Demand and Increased Average Contract Value (7 articles)